Multiple Sklerose und Fettsäuren – historischer und aktueller Studienstand

Zusammenfassung

Schon in den 1950er-Jahren gab es Hinweise auf Zusammenhänge zwischen Fettsäuren in der Ernährung und Multipler Sklerose (MS). In den kommenden Jahrzehnten konnte dann aufgedeckt werden, über welche Mechanismen bestimmte Fettsäuren pro- oder anti-inflammatorisch wirken. Weitere Studien konnten belegen, dass die Omega-3-Fettsäuren EPA/DHA Entzündungsmediatoren senken können. Weitere Symptome wie Depression, Schübe oder Stoffwechselparameter konnten laut Studien ebenfalls gebessert werden.

Abstract

Already in the 1950s there were indications of a connection between fatty acids in the diet and multiple sclerosis (MS). In the decades that followed, it was possible to discover the mechanisms by which certain fatty acids have a pro-inflammatory or anti-inflammatory effect. Further studies have shown that the omega-3 fatty acids EPA/DHA can reduce inflammation mediators. According to studies, it has also been possible, to improve other symptoms such as depression, relapses or metabolic parameters.

Schlüsselwörter

Multiple Sklerose - Fettsäuren - ALA - EPA - DHA - Depression

Key words

Multiple sclerosis - fatty acids - ALA - EPA - DHA - depression

• Literatur

• 1 Swank RL. Multiple sclerosis: A correlation of its incidence with dietary fat. Am J Med Sci 1950; 220: 421-430
• 2 Bernsohn J, Stephanides LM. Aetiology of multiple sclerosis. Nature 1967; 215 (5103) 821-823
• 3 Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990; 336: 37-39
• 4 Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. Oxid Med Cell Longev. 2013
• 5 Kouchaki E, Afarini M, Abolhassani J. et al. High-dose ω-3 fatty acid plus vitamin D3 supplementation affects clinical symptoms and metabolic status of patients with multiple sclerosis: A randomized controlled clinical trial. J Nutr 2018; 148 (08) 1380-1386
• 6 Shinto L, Marracci G, Baldauf-Wagner S. et al. Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids 2009; 80 (02/03) 131-136
• 7 Shinto L, Marracci G, Mohr DC. et al. Omega-3 fatty acids for depression in multiple sclerosis: A randomized pilot study. PLoS One. 2016
• 8 Taylor KL, Hadgkiss EJ, Jelinek GA. et al. Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis. BMC Psychiatry. 2014
• 9 Kontogianni MD, Vlassopoulos A, Gatzieva A. et al. Flaxseed oil does not affect inflammatory markers and lipid profile compared to olive oil, in young, healthy, normal weight adults. Metabolism 2013; 62 (05) 686-693
• 10 Crawford MA, Costeloe K, Ghebremeskel K. et al. Are deficits of arachidonic and docosahexaenoic acids responsible for the neural and vascular complications of preterm babies?. Am J Clin Nutr 1997; 66 (Suppl. 04) 1032S-1041S
• 11 Greupner T, Kutzner L, Nolte F. et al. Effects of a 12-week high-α-linolenic acid intervention on EPA and DHA concentrations in red blood cells and plasma oxylipin pattern in subjects with a low EPA and DHA status. Food Funct 2018; 9 (03) 1587-1600